United States
Print page content Print
Increase text size Decrease text size
Text Size

LEUKOCELL® 2

FeLV vaccine with the tumor-specific antigen FOCMA to aid in tumor protection

LEUKOCELL 2

LEUKOCELL 2 is a multiple viral antigen vaccine for vaccination of healthy cats 9 weeks of age or older as an aid in preventing persistent viremia, lymphoid tumors caused by feline leukemia virus (FeLV) and diseases associated with FeLV infection.

Expand All
    • Demonstrated efficacy in helping prevent persistent viremia, lymphoid tumors and FeLV-associated diseases.
    • A FeLV vaccine with the tumor-specific antigen FOCMA (feline oncornavirus-associated cell membrane antigen) to aid in tumor protection.
    • Prepared from a FeLV-transformed lymphoid cell line that releases soluble FeLV particles into cell culture medium, reducing the immunosuppressive effects of fully assembled, inactivated FeLV antigens.
    • LEUKOCELL 2 is supported by our Companion Animal Immunization Support Guarantee (ISG).
  • Directions:

    1. General Directions: Shake well. Aseptically administer 1 mL subcutaneously.

    2. Primary Vaccination: Healthy cats 9 weeks of age or older should receive 2 doses administered 3-4 weeks apart.

    3. Revaccination: Annual revaccination with a single dose is recommended.


Precaution(s): Store at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.

Use entire contents when first opened.

Sterilized syringes and needles should be used to administer this vaccine.

Caution(s): Certain post-vaccination reactions may occur. Post-vaccination reactions have been observed in about 2% of vaccinated cats. These included stinging on injection, transient listlessness, depression, and brief temperature elevations. Hypersensitivity evidenced by myxedema and gastrointestinal distress (vomiting and bowel evacuation) occasionally has been reported.

Although a diagnostic test for FeLV antigen is not required prior to vaccination with LEUKOCELL® 2, such a test may be beneficial in evaluating candidates for vaccination. Vaccination is of no known therapeutic value in cats with existing FeLV infection, nor will it alter the natural course of disease.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnouished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

Technical inquiries should be directed to Zoetis Veterinary Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).

For veterinary use only.